Login to Your Account



Immune Design gets FDA blessing, goes pivotal with CMB-305 in synovial sarcoma

By Marie Powers
News Editor

Tuesday, October 17, 2017

Immune Design Corp. said the FDA blessed its plans to initiate a pivotal phase III of CMB-305, its prime-boost vaccine approach against NY-ESO-1-expressing tumors, in individuals with locally advanced unresectable or metastatic synovial sarcoma, a subtype of soft tissue sarcoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription